A Prospective Randomized Crossover Trial of Systemic Chemotherapy in
Title Patients
of the Poster
Presentation
Goes Here
with Low-Grade
Mucinous
Appendiceal Adenocarcinoma

Authors Abdelrahman
of the Poster
Presentation
Goes
1, John Paul
M. Yousef
Shen1Here
, Fadl Zeineddine1, Mohammad Zeineddine1, Rebecca Slack Tidwell1, Robert A. Wolff1, Aurelio Matamoros1, Wai Chin
Institutional
Graduate
of Biomedical
Sciences
Affiliation
Here
1, Melissa
1, Abhineet
1, Paul Goes
1, Safia Rafeeq1, Kanwal Raghav1, Michael J. Overman1, Keith Fournier1
Fooand/or
TaggartSchool
Uppal1 ,Christopher
Scally
Mansfield
1The

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background
•

•

Fig 2. (A) Percent change in tumor
size by mpRECIST method between
observation and treatment. A novel
quantitative measuring system
designed for mucinous peritoneal
disease, measures up to 5 areas of
mucinous disease in the abdominal
cavity. Spider plots showing tumor
growth over time in observation first
arm (B) and tumor growth overtime in
treatment first arm (C). (D) Waterfall
plot showing best overall response
after treatment period

Appendiceal adenocarcinoma (AA) is both a rare and
heterogenous tumor. The rarity of appendiceal
adenocarcinoma has made it difficult to study with traditional
prospective, randomized controlled trials. As a result, current
national guidelines still suggest that appendiceal cancer be
treated similarly to colorectal cancer (CRC)
While low-grade AA is primarily treated with surgical
resection sometimes followed by hyperthermic intraperitoneal
chemotherapy (HIPEC), many inoperable candidates are
treated with systemic chemotherapy although there is no
prospective data supporting this practice. The purpose of our
study was to objectively evaluate the effectiveness of
systemic chemotherapy in low-grade mucinous AA

•

•

•

Patient reported quality of life (QOL) metrics identified
that fatigue (p=0.02), peripheral neuropathy (p=0.014),
and financial difficulty (p=0.0013) were all significantly
worse while on treatment
There was no significant difference between
observation and treatment periods for the percent
change in any of the tumor markers evaluated, CEA,
CA-125 and CA 19-9
The mean percent change in tumor markers for
observation and treatment were 50% vs 4% for CEA
(p=0.23), 2% vs 2% for CA-125 (p=0.99), and 13% vs 6%
for CA 19-9 (p=0.39)

Patients and Methods
•

•

A randomized crossover trial of surgically unresectable lowgrade mucinous AA was performed with patients randomized
to either 6 months observation followed by 6 months of
chemotherapy, or initial chemotherapy followed by
observation
Enrollment of up to 30 patients was planned to have complete
6- and 12-month tumor measurements for 24 patients,
providing 80% power and α=0.05 to detect a 5.0% difference in
tumor growth, as measured by modified peritoneal RECIST,
when comparing the observation and treatment periods

Fig 1. (A) CONSORT flow diagram. (B) Study design. Total study duration is 12
months

•

•
•

•

Results
•

A total of 24 patients were enrolled. The majority of patients
were treated with either 5FU or capecitabine as single agent (n
= 15, 63%); 3 (13%) received doublet chemotherapy (FOLFOX
or FOLFIRI), bevacizumab was added to cytotoxic
chemotherapy for 5 (21%) patients. Fifteen patients were
available to evaluate primary endpoint of difference in tumor
growth between treatment and observations

The mean difference in tumor size was -4.5 (95% CI: -12.6,
3.7), indicating a trend towards faster growth on
treatment than observation, however there was no
significant difference in growth of tumor during
observation vs. treatment time periods (8.4% growth
treatment vs. 4.0% observation, p=0.26)
Of the 18 patients who received any chemotherapy, zero
had an objective response (14 (77.8%) SD, 4 (22.2 %) PD)
Median OS was 53.2 months, there was no significant
difference in OS between the Observation First arm (76
months) and the Treatment First arm (53 months) (HR,
0.64; 95% CI, 0.16 to 2.6; p = 0.48)
There was not a significant difference in rate of bowel
obstruction between the treatment first vs. observation
first arms (12.5%, (n=3) vs 8.3%, (n=2)), and no bowel
perforations occurred on study

Fig 3. Kaplan Meier curves showing Overall survival of all patients (A) and between the
two groups (B). Swimmer plots showing treatment history overtime for observation
first arm (C) and Treatment first arm (D). The pie chart shows the chemotherapy
distribution patients received during the trial period

Fig 4. patients
reported
outcomes.
EORTC quality
of life
questionnaire
results

Fig 5. Spider plots showing tumor markers level over time. (A) CEA levels in
observation-first arm on the left and treatment-first arm on the right. (B)
CA19-9 levels in observation-first arm on the left and treatment-first arm on
the right

Conclusions
•

In summary, these data from a prospective, randomized
crossover design trial indicate that patients with lowgrade mucinous AA do not derive benefit from
flouropyrimidine-based chemotherapy

•

We therefore conclude that fluoropyrimidine-based
chemotherapy should not be used in this specific patient
population

•

These data demonstrate the unique biology of low-grade
mucinous AAs and highlight the need for more preclinical and clinical investigation for this orphan disease
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